Dr Ken O'Byrne is President of the British Mesothelioma Trust.Professor Valerie Rusch, M.D. is currently Chief of Thoracic Surgery at Memorial Sloan-Kettering Cancer Center, where she also holds the William G. Cahan Chair. She is a member of the Editorial Boards for The Journal of Thoracic and Cardiovascular Surgery, The Journal of Clinical Oncology, The Oncologist, and Lung Cancer.

...this book is one of the best. ...Anybody dealing with diffuse malignant mesothelioma, in either a research or clinical setting, should learn a great deal from this book in topics outside his or her own immediate specializations.

• SECTION 1. CLINICAL FEATURES OF MESOTHELIOMA ; 1. The Epidemiology and Aetiology of Malignant Mesothelioma ; 2. Epidemiological Snapshots From Around the World ; 3. Clinical Presentation, Radiological Evaluation and Diagnosis ; 4. Histopathology of Malignant Pleural Mesothelioma ; 5. Clinico-Pathological Prognostic Factors & Scoring Systems in Malignant Pleural Mesothelioma ; SECTION 2. BIOLOGY OF MESOTHELIOMA ; 6. Carcinogenic Mechanisms in Mesothelioma: Effects of asbestos on cell signal events, transcription factors, and inflammatory cytokines ; 7. Viral Factors in the Pathogenesis of Malignant Mesothelioma ; 8. Growth Factors, Cyclooxygenease-2 and Matrix Metalloproteinases in Malignant Mesothelioma ; 9. Vascularisation in Malignant Mesothelioma ; 10. Immunobiology of Malignant Mesothelioma ; 11. Cytogenetic and Molecular Genetic Changes in Malignant Mesothelioma ; SECTION 3. TREATMENT STRATEGIES ; 12. The Role of Surgery for Diagnosis, Staging and Symptom Control in Malignant Pleural Mesothelioma ; 13. Surgical and Multimodality Approaches to the Management of Operable Malignant Mesothelioma ; 14. Systemic Chemotherapy for Malignant Pleural Mesothelioma ; 15. Radiotherapy for Mesothelioma ; 16. Immunotherapy for Malignant Mesothelioma ; 17. Intra-thoracic Photodynamic Diagnosis and Treatment with Photodynamic Therapy or Hyperthermia of Malignant Mesothelioma ; 18. Novel Therapies for Mesothelioma ; 19. Gene Therapy for Malignant Pleural Mesothelioma ; 20. Palliative Care for Mesothelioma ; 21. The Treatment of Mesothelioma Cases in the American and United Kingdom Legal Systems

Dr Ken O'Byrne is President of the British Mesothelioma Trust.Professor Valerie Rusch, M.D. is currently Chief of Thoracic Surgery at Memorial Sloan-Kettering Cancer Center, where she also holds the William G. Cahan Chair. She is a member of the Editorial Boards for The Journal of Thoracic and Cardiovascular Surgery, The Journal of Clinical Oncology, The Oncologist, and Lung Cancer.

...this book is one of the best. ...Anybody dealing with diffuse malignant mesothelioma, in either a research or clinical setting, should learn a great deal from this book in topics outside his or her own immediate specializations.

• SECTION 1. CLINICAL FEATURES OF MESOTHELIOMA ; 1. The Epidemiology and Aetiology of Malignant Mesothelioma ; 2. Epidemiological Snapshots From Around the World ; 3. Clinical Presentation, Radiological Evaluation and Diagnosis ; 4. Histopathology of Malignant Pleural Mesothelioma ; 5. Clinico-Pathological Prognostic Factors & Scoring Systems in Malignant Pleural Mesothelioma ; SECTION 2. BIOLOGY OF MESOTHELIOMA ; 6. Carcinogenic Mechanisms in Mesothelioma: Effects of asbestos on cell signal events, transcription factors, and inflammatory cytokines ; 7. Viral Factors in the Pathogenesis of Malignant Mesothelioma ; 8. Growth Factors, Cyclooxygenease-2 and Matrix Metalloproteinases in Malignant Mesothelioma ; 9. Vascularisation in Malignant Mesothelioma ; 10. Immunobiology of Malignant Mesothelioma ; 11. Cytogenetic and Molecular Genetic Changes in Malignant Mesothelioma ; SECTION 3. TREATMENT STRATEGIES ; 12. The Role of Surgery for Diagnosis, Staging and Symptom Control in Malignant Pleural Mesothelioma ; 13. Surgical and Multimodality Approaches to the Management of Operable Malignant Mesothelioma ; 14. Systemic Chemotherapy for Malignant Pleural Mesothelioma ; 15. Radiotherapy for Mesothelioma ; 16. Immunotherapy for Malignant Mesothelioma ; 17. Intra-thoracic Photodynamic Diagnosis and Treatment with Photodynamic Therapy or Hyperthermia of Malignant Mesothelioma ; 18. Novel Therapies for Mesothelioma ; 19. Gene Therapy for Malignant Pleural Mesothelioma ; 20. Palliative Care for Mesothelioma ; 21. The Treatment of Mesothelioma Cases in the American and United Kingdom Legal Systems

Dr Ken O'Byrne is President of the British Mesothelioma Trust.Professor Valerie Rusch, M.D. is currently Chief of Thoracic Surgery at Memorial Sloan-Kettering Cancer Center, where she also holds the William G. Cahan Chair. She is a member of the Editorial Boards for The Journal of Thoracic and Cardiovascular Surgery, The Journal of Clinical Oncology, The Oncologist, and Lung Cancer.

...this book is one of the best. ...Anybody dealing with diffuse malignant mesothelioma, in either a research or clinical setting, should learn a great deal from this book in topics outside his or her own immediate specializations.

• SECTION 1. CLINICAL FEATURES OF MESOTHELIOMA ; 1. The Epidemiology and Aetiology of Malignant Mesothelioma ; 2. Epidemiological Snapshots From Around the World ; 3. Clinical Presentation, Radiological Evaluation and Diagnosis ; 4. Histopathology of Malignant Pleural Mesothelioma ; 5. Clinico-Pathological Prognostic Factors & Scoring Systems in Malignant Pleural Mesothelioma ; SECTION 2. BIOLOGY OF MESOTHELIOMA ; 6. Carcinogenic Mechanisms in Mesothelioma: Effects of asbestos on cell signal events, transcription factors, and inflammatory cytokines ; 7. Viral Factors in the Pathogenesis of Malignant Mesothelioma ; 8. Growth Factors, Cyclooxygenease-2 and Matrix Metalloproteinases in Malignant Mesothelioma ; 9. Vascularisation in Malignant Mesothelioma ; 10. Immunobiology of Malignant Mesothelioma ; 11. Cytogenetic and Molecular Genetic Changes in Malignant Mesothelioma ; SECTION 3. TREATMENT STRATEGIES ; 12. The Role of Surgery for Diagnosis, Staging and Symptom Control in Malignant Pleural Mesothelioma ; 13. Surgical and Multimodality Approaches to the Management of Operable Malignant Mesothelioma ; 14. Systemic Chemotherapy for Malignant Pleural Mesothelioma ; 15. Radiotherapy for Mesothelioma ; 16. Immunotherapy for Malignant Mesothelioma ; 17. Intra-thoracic Photodynamic Diagnosis and Treatment with Photodynamic Therapy or Hyperthermia of Malignant Mesothelioma ; 18. Novel Therapies for Mesothelioma ; 19. Gene Therapy for Malignant Pleural Mesothelioma ; 20. Palliative Care for Mesothelioma ; 21. The Treatment of Mesothelioma Cases in the American and United Kingdom Legal Systems